Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
In the latest session, Roivant Sciences Ltd (NASDAQ: ROIV) closed at $20.23 up 1.81% from its previous closing price of $19.87. In other words, the price has increased by $1.81 from its previous closing price. On the day, 9.9 million shares were traded. ROIV stock price reached its highest trading level at $20.3 during the session, while it also had its lowest trading level at $19.615.
Ratios:
For a deeper understanding of Roivant Sciences Ltd’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 40.54 and its Current Ratio is at 40.54. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Citigroup on September 02, 2025, initiated with a Buy rating and assigned the stock a target price of $16.
On February 15, 2024, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $17.Wolfe Research initiated its Outperform rating on February 15, 2024, with a $17 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 15 ’25 when Venker Eric sold 414,683 shares for $16.93 per share. The transaction valued at 7,020,583 led to the insider holds 1,504,959 shares of the business.
Venker Eric sold 318,282 shares of ROIV for $5,426,708 on Oct 16 ’25. The President & Immunovant CEO now owns 1,504,959 shares after completing the transaction at $17.05 per share. On Oct 17 ’25, another insider, Venker Eric, who serves as the President & Immunovant CEO of the company, sold 118,418 shares for $17.06 each. As a result, the insider received 2,020,211 and left with 1,504,959 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ROIV now has a Market Capitalization of 13814696960 and an Enterprise Value of 9635675136. For the stock, the TTM Price-to-Sale (P/S) ratio is 594.69 while its Price-to-Book (P/B) ratio in mrq is 3.18. Its current Enterprise Value per Revenue stands at 414.741 whereas that against EBITDA is -8.392.
Stock Price History:
The Beta on a monthly basis for ROIV is 1.23, which has changed by 0.68962586 over the last 52 weeks, in comparison to a change of 0.13367426 over the same period for the S&P500. Over the past 52 weeks, ROIV has reached a high of $20.08, while it has fallen to a 52-week low of $8.73. The 50-Day Moving Average of the stock is 27.90%, while the 200-Day Moving Average is calculated to be 66.08%.
Shares Statistics:
For the past three months, ROIV has traded an average of 7.69M shares per day and 8795810 over the past ten days. A total of 682.23M shares are outstanding, with a floating share count of 415.35M. Insiders hold about 39.18% of the company’s shares, while institutions hold 64.05% stake in the company. Shares short for ROIV as of 1760486400 were 25271869 with a Short Ratio of 3.29, compared to 1757894400 on 36208272. Therefore, it implies a Short% of Shares Outstanding of 25271869 and a Short% of Float of 4.96.
Earnings Estimates
Currently, 4.0 analysts are dedicated to thoroughly evaluating and rating the performance of Roivant Sciences Ltd (ROIV) in the stock market.The consensus estimate for the next quarter is -$0.31, with high estimates of -$0.25 and low estimates of -$0.42.
Analysts are recommending an EPS of between -$0.95 and -$1.56 for the fiscal current year, implying an average EPS of -$1.16. EPS for the following year is -$1.29, with 4.0 analysts recommending between -$1.02 and -$1.82.
Revenue Estimates
A total of 7 analysts believe the company’s revenue will be $6.92M this quarter.It ranges from a high estimate of $15M to a low estimate of $1.78M. As of. The current estimate, Roivant Sciences Ltd’s year-ago sales were $29.26MFor the next quarter, 7 analysts are estimating revenue of $7.1M. There is a high estimate of $15M for the next quarter, whereas the lowest estimate is $1.78M.
A total of 9 analysts have provided revenue estimates for ROIV’s current fiscal year. The highest revenue estimate was $47.2M, while the lowest revenue estimate was $2.17M, resulting in an average revenue estimate of $21.43M. In the same quarter a year ago, actual revenue was $29.05MBased on 9 analysts’ estimates, the company’s revenue will be $169.95M in the next fiscal year. The high estimate is $567.77M and the low estimate is $11.81M.
